| Literature DB >> 34080260 |
Dan-Hua He1,2, Yu-Fei Chen1,2, Yi-Le Zhou1, Shi-Bing Zhang1, Ming Hong1, Xianjun Yu3, Su-Fen Wei1, Xiang-Zhen Fan1, Si-Yi Li1, Qi Wang1, Yongzhi Lu4,5, Yong-Qiang Liu1,2.
Abstract
Skp2 is overexpressed in multiple cancers and plays a critical role in tumor development through ubiquitin/proteasome-dependent degradation of its substrate proteins. Drugs targeting Skp2 have exhibited promising anticancer activity. Here, we identified a plant-derived Skp2 inhibitor, betulinic acid (BA), via high-throughput structure-based virtual screening of a phytochemical library. BA significantly inhibited the proliferation and migration of non-small cell lung cancer (NSCLC) through targeting Skp2-SCF E3 ligase both in vitro and in vivo. Mechanistically, BA binding to Skp2, especially forming H-bonds with residue Lys145, decreases its stability by disrupting Skp1-Skp2 interactions, thereby inhibiting the Skp2-SCF E3 ligase and promoting the accumulation of its substrates; that is, E-cadherin and p27. In both subcutaneous and orthotopic xenografts, BA significantly inhibited the proliferation and metastasis of NSCLC through targeting Skp2-SCF E3 ligase and upregulating p27 and E-cadherin protein levels. Taken together, BA can be considered a valuable therapeutic candidate to inhibit metastasis of NSCLC.Entities:
Keywords: E-cadherin; NSCLC; Skp2; betulinic acid; metastasis
Year: 2021 PMID: 34080260 DOI: 10.1111/cas.15005
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716